GLP-1 Weight Loss Injections at Med Spas: The Compliance Crackdown You Need to Know About

GLP-1 Became the Med Spa Industry's Fastest-Growing Service — and Its Biggest Compliance Risk

When semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) became the most talked-about medical treatments of the 2020s, med spas were well-positioned to offer weight loss programs. The demand was enormous. The margins were attractive. And for a period, compounding pharmacies were legally able to produce semaglutide because the branded versions were in declared shortage status with the FDA.

That window is now closed. And the regulatory response to how some providers behaved during that window is substantial.

The FDA Compounding Ban: What Happened and Why It Matters

Under federal law, compounding pharmacies can legally produce copies of FDA-approved drugs when those drugs are in declared shortage. When the FDA declared semaglutide and tirzepatide in shortage, the compounding pathway opened — and hundreds of med spas began offering compounded semaglutide and tirzepatide weight loss programs, often at a fraction of the branded product price.

When Novo Nordisk and Eli Lilly expanded production capacity and the FDA determined the shortage was resolved, the legal basis for most compounded GLP-1s evaporated. Effective May 22, 2025, most compounded semaglutide and tirzepatide became unavailable, according to the American Board of Cosmetic Surgery and FDA guidance. Limited individualized compounding exceptions remained for patients with specific documented clinical needs — but the broad "shortage" pathway closed.

Med spas that continued offering compounded GLP-1 products after May 2025 — either by maintaining existing inventory or by continuing to source from compounders — were operating in violation of federal drug law.

The Warning Letters: FDA Named Names

On September 9, 2025, the FDA issued more than 55 warning letters to online and in-person sellers of compounded GLP-1 products. Several were directed specifically at med spas. Named recipients included Invigorate Med Spa and Cosmo Medical Spa (dba Cosmo Med Spa) — both cited for false and misleading claims about their compounded semaglutide and tirzepatide products.

The FDA's warning letters cited violations of Sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act — provisions that prohibit false or misleading labeling and claims that misrepresent a drug as FDA-approved when it is not. Specifically cited as violations in the warning letters:

• Language implying compounded products are "the same" as FDA-approved branded GLP-1 medications
• Claims of "clinically proven weight loss treatments" applied to compounded formulations
• Marketing that described the active ingredient of compounded products using branded names (e.g., "semaglutide" described as the same as "Wegovy")
• In one letter, even the language "Doctors frequently recommend Compounded Tirzepatide or Compounded Semaglutide, both of which are GLP-1 agonists with the same active ingredient as the brand name medications" was flagged as a violation

These warning letters require the recipient to respond within 15 working days outlining how they will correct the violations. Failure to respond or correct can lead to additional enforcement action including injunction, product seizure, or criminal prosecution under the FDCA.

State-Level Enforcement: Attorneys General Step In

The FDA isn't the only enforcement authority in this space. In December 2025, more than 40 state attorneys general sent a joint letter to the FDA describing what they characterized as a national ecosystem of counterfeit, contaminated, and research-grade GLP-1 products entering the U.S. through unregulated channels. The AGs specifically flagged:

• Counterfeit semaglutide imported from China, Turkey, and India, repackaged as FDA-approved products
• Products with false labeling identifying non-existent compounding pharmacies
• Contamination risks from unregulated manufacturing conditions
• Consumer harm from these products being sold at what appeared to be legitimate healthcare settings

The FDA itself noted in February 2026 that it was aware of fraudulent compounded semaglutide and tirzepatide being marketed in the U.S. with false product labels — in some cases naming compounding pharmacies that do not exist.

Med spas that sourced GLP-1 products through unverified channels — motivated by lower costs — face both federal and state-level exposure if those products turn out to be counterfeit or contaminated.

What a Compliant GLP-1 Weight Loss Program Looks Like in 2026

If you want to offer GLP-1 weight loss services at your med spa, the compliance framework has tightened considerably. Here is what a properly structured program requires:

1. Prescribing Physician Authority

GLP-1 medications — whether Wegovy, Ozempic, Mounjaro, or Zepbound — are prescription drugs. Every patient who receives a GLP-1 injection must have a valid prescription issued by a licensed prescribing physician who has performed or reviewed a clinical evaluation of that patient. A telehealth prescription model is permissible in many states but requires a legitimate physician-patient relationship and documented clinical evaluation.

2. Patient Screening and Eligibility Documentation

FDA-approved GLP-1 medications have specific indications: Wegovy is approved for chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related condition. Your prescribing protocol must specify these eligibility criteria and document that each patient was evaluated against them. Administering GLP-1s to patients who do not meet the clinical criteria is off-label prescribing that carries additional liability and regulatory exposure.

3. Licensed Product Sourcing Only

All GLP-1 products used at your facility must be sourced from licensed U.S. pharmaceutical distributors. Documentation of the supply chain — manufacturer, distributor, lot numbers, expiration dates — should be maintained. Any product arriving through non-standard channels, or priced substantially below market for branded medications, should be treated as suspect.

4. Compliant Marketing

Based on the FDA's September 2025 warning letters, every med spa marketing weight loss injection services should have their materials reviewed for compliance. Specifically:

• Do not claim that any injectable product is "the same as" Wegovy, Ozempic, Mounjaro, or any other FDA-approved GLP-1
• Do not apply "clinically proven" claims to compounded formulations
• Do not use branded drug names to describe what your program offers unless you are actually prescribing those branded products
• Do not imply FDA approval for any compounded formulation

5. Monitoring and Adverse Event Protocols

GLP-1 medications have documented adverse effects including nausea, vomiting, gallbladder disease, pancreatitis, and thyroid tumor risk. A compliant weight loss program includes a monitoring protocol that specifies follow-up intervals, what to assess at each visit, symptoms requiring escalation, and an adverse event response procedure. These protocols must be written, physician-approved, and documented in each patient's record.

The Counterfeiting Problem Is Real and It Affects You

One issue that has complicated compliance for even well-intentioned med spas: the market for counterfeit GLP-1 products. The FDA and 40+ state AGs identified products being sold with false labels identifying compounding pharmacies that don't exist. Some of these products were entering the supply chain through channels that appeared legitimate.

If a patient is harmed by a counterfeit or contaminated GLP-1 product that was administered at your spa, the fact that you didn't know it was counterfeit is not a complete defense. The question regulators and plaintiffs' attorneys will ask is: what steps did you take to verify the source and integrity of the products you administered? Documented supply chain verification — buying only from licensed U.S. distributors and maintaining lot number records — is your best protection.

If You're Audited: What Investigators Look For in a GLP-1 Program

Based on the pattern of FDA and state enforcement actions, here is what an investigator examining your GLP-1 program will focus on:

1. Source of the product — Was it sourced from a licensed U.S. distributor? Do you have documentation?
2. Prescribing process — Was each patient evaluated by a physician before receiving a prescription? Is that evaluation documented?
3. Marketing claims — Do your website, social media, or in-spa materials make any claims that could be construed as misrepresenting compounded products as FDA-approved?
4. Protocols — Do you have written, physician-signed protocols for patient screening, monitoring, and adverse event response?
5. Informed consent — Did patients sign an informed consent document that covers the risks and nature of the treatment?

Med spas that can produce affirmative documentation for each of these questions are in a dramatically stronger position than those who cannot — even if minor procedural issues exist elsewhere.

The Opportunity Remains — For Compliant Providers

It's worth noting that the regulatory tightening around GLP-1 services is not a signal that weight loss programs are off-limits for med spas. Demand for physician-supervised weight loss programs remains strong. The FDA-approved products — Wegovy, Zepbound, and the others — are widely prescribed and can be legally offered through properly structured med spa weight loss programs.

The crackdown is specifically targeting providers who were operating outside the rules: selling compounded versions after the ban, making false marketing claims, sourcing through unregulated channels. For med spas with a properly structured program — physician prescribing, compliant sourcing, written protocols, accurate marketing — GLP-1 weight loss services remain a viable service line.

The key is building that infrastructure now and not waiting until an FDA warning letter arrives at your address.

Disclaimer: This article is for educational purposes only and does not constitute legal or regulatory advice. FDA and state regulations regarding GLP-1 medications and compounding continue to evolve. Consult with a licensed healthcare attorney and pharmacist for guidance specific to your practice.